Posted by Michael Wonder on 07 Jan 2022
AbbVie submits applications for upadacitinib (Rinvoq) in non-radiographic axial spondyloarthritis to U.S. FDA and EMA
7 January 2022 - Submissions supported by Phase 3 study in which upadacitinib (Rinvoq) demonstrated significant improvements in signs and symptoms as well as physical function and disease activity versus placebo.
AbbVie today announced that it has submitted applications seeking approvals for upadacitinib (Rinvoq, 15 mg once daily) to the U.S. FDA and the EMA for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have responded inadequately to non-steroidal anti-inflammatory drugs.
